TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.